相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas
Maximillian Rosario et al.
CLINICAL CANCER RESEARCH (2016)
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2016)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych et al.
CLINICAL CANCER RESEARCH (2016)
In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing
Steffi Lehmann et al.
CLINICAL CANCER RESEARCH (2016)
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses
Bai Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
Kelly D. Moynihan et al.
NATURE MEDICINE (2016)
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
Tilman Schlothauer et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2016)
Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2
Natalia Arenas-Ramirez et al.
Science Translational Medicine (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
Reza Ghasemi et al.
NATURE COMMUNICATIONS (2016)
IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation
Geok Choo Sim et al.
CANCER IMMUNOLOGY RESEARCH (2016)
CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
Marina Bacac et al.
ONCOIMMUNOLOGY (2016)
Game, set, match for factor VIII mismatch?
Connie H. Miller
BLOOD (2015)
Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
Eric F. Zhu et al.
CANCER CELL (2015)
Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms
Jamie B. Spangler et al.
IMMUNITY (2015)
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
Alice Tzeng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
interleukin-2: Biology, Design and Application
Natalia Arenas-Ramirez et al.
TRENDS IN IMMUNOLOGY (2015)
The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy
Thomas A. Waldmann
CANCER IMMUNOLOGY RESEARCH (2015)
Improving the Therapeutic Index in Cancer Therapy by Using Antibody-Drug Conjugates Designed with a Moderately Cytotoxic Drug
Serengulam V. Govindan et al.
MOLECULAR PHARMACEUTICS (2015)
GA201: A Novel Humanized and Glycoengineered Anti-EGFR Antibody-Response
Christian A. Gerdes et al.
CLINICAL CANCER RESEARCH (2014)
IL-2: The First Effective Immunotherapy for Human Cancer
Steven A. Rosenberg
JOURNAL OF IMMUNOLOGY (2014)
CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
Michael D. Oberst et al.
MABS (2014)
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Mahesh Yadav et al.
NATURE (2014)
Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor αSu/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma
Wenxin Xu et al.
CANCER RESEARCH (2013)
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
Silke Gillessen et al.
EUROPEAN JOURNAL OF CANCER (2013)
Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2
Tania Carmenate et al.
JOURNAL OF IMMUNOLOGY (2013)
Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy
Melissa G. Lechner et al.
JOURNAL OF IMMUNOTHERAPY (2013)
The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+ T cells into innate-like effector cells with antitumor activity
Hing C. Wong et al.
ONCOIMMUNOLOGY (2013)
Antibody-cytokine fusion proteins
Roland E. Kontermann
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
Homeostatic maintenance of T cells and natural killer cells
Onur Boyman et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
Immunocytokines: a novel class of potent armed antibodies
Nadine Pasche et al.
DRUG DISCOVERY TODAY (2012)
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
Aron M. Levin et al.
NATURE (2012)
Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15
Aaron M. Ring et al.
NATURE IMMUNOLOGY (2012)
The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA
Li Peng et al.
PLOS ONE (2012)
The role of interleukin-2 during homeostasis and activation of the immune system
Onur Boyman et al.
NATURE REVIEWS IMMUNOLOGY (2012)
A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
Stephen D. Gillies et al.
CLINICAL CANCER RESEARCH (2011)
A Combination of Serum Markers for the Early Detection of Colorectal Cancer
Norbert Wild et al.
CLINICAL CANCER RESEARCH (2010)
Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
Carsten Krieg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
Christoph Schliemann et al.
BLOOD (2009)
Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis
S. Q. Ashraf et al.
BRITISH JOURNAL OF CANCER (2009)
Antibody-cytokine fusion proteins:: applications in cancer therapy
Elizabeth Ortiz-Sanchez et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
IL-2 Family of Cytokines in T Regulatory Cell Development and Homeostasis
Thomas R. Malek et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2008)
Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease
Onur Boyman et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2006)
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Thomas A. Waldmann
NATURE REVIEWS IMMUNOLOGY (2006)
Selective stimulation of T cell subsets with antibody-cytokine immune complexes
O Boyman et al.
SCIENCE (2006)
Structure of the quaternary complex of interleukin-2 with its α, β, and γc receptors
XQ Wang et al.
SCIENCE (2005)
A function for interleukin 2 in Foxp3-expressing regulatory T cells
JD Fontenot et al.
NATURE IMMUNOLOGY (2005)
Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling
LM D'Cruz et al.
NATURE IMMUNOLOGY (2005)
The structure of interleukin-2 complexed with its alpha receptor
M Rickert et al.
SCIENCE (2005)
Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors
RW Wilkinson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
